PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma

DISCUSSION: This trial is set up to assess first indications of clinical efficacy and tolerability of perampanel in recurrent glioblastoma, a repurposed drug which inhibits neuron-glioma synapses and thereby glioblastoma growth in preclinical models. If perampanel proved to be successful in the clinical setting, it would provide the first evidence that interference with neuron-cancer interactions may indeed lead to a benefit for patients, which would lay the foundation for a larger confirmatory trial in the future.TRIAL REGISTRATION: EU-CT number: 2023-503938-52-00 30.11.2023.PMID:38279087 | PMC:PMC10811925 | DOI:10.1186/s12885-024-11846-1

Source: Methods of Information in Medicine - January 26, 2024 Category: Information Technology Authors: Sophie Heuer Ina Burghaus Maria Gose Tobias Kessler Felix Sahm Philipp Vollmuth Varun Venkataramani Dirk Hoffmann Matthias Schlesner Miriam Ratliff Carsten Hopf Ulrich Herrlinger Franz Ricklefs Martin Bendszus Sandro M Krieg Antje Wick Wolfgang Wick Frank Source Type: research